ANNAMARIA GRAFFEO: Open Payments
NPI 1336867068 · DANVERS, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,522 in 146 payments from 12 companies in 2025. Trend: 2023 $1,897 · 2024 $2,201 · 2025 $3,522
Food & beverage: $3,498Education: $23
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 24 | $770 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $516 |
| Alkermes, Inc. | 20 | $485 |
| Otsuka America Pharmaceutical, Inc. | 16 | $342 |
| Vanda Pharmaceuticals Inc. | 18 | $320 |
| Janssen Pharmaceuticals, Inc | 12 | $305 |
| E.R. Squibb & Sons, L.L.C. | 15 | $299 |
| Lundbeck LLC | 11 | $252 |
| ABBVIE INC. | 7 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
Products named: INGREZZA, REXULTI, CAPLYTA, FANAPT, ARISTADA, COBENFY, INVEGA SUSTENNA, LYBALVI.
Industry payments across MA — which companies pay providers there.
